Previous clients:

1) New Jersey Biotech company (3 programs – two novel dry powder airway disease/delivery projects and additional antiviral project)

2) Japanese pharmaceutical company (inhaled antibiotic for US – led their pre-IND meeting)

3) California based contract research organization/clinical site (multiple programs – mostly topical drug delivery to airways)

4) California Translational Science Institute – T1 Catalyst Project – Early Translational Research []

5) Oligonucleotide company (neuromuscular disease)

6) San Francisco Bay Area urology device company (preparing their NDA)

7) East Coast based, large pharma (inhaled/pulmonary drug(s))

8) Global oligonucleotide company (gastrointestinal indication)

9) Small East Coast company (drug repurposing)

10) Oligonucleotide Safety Working Group – Publications coordinator []

and recent/current clients (in 2023 and beyond):

11) Taiwan based biosimilar manufacturer – multiple programs

12) Multiple Nasal Delivery companies (based in US, Ireland, Israel, India & Switzerland)

13) San Diego dermatology focused start up

14) European inhaled formulation CDMO

15) Editor & author for a global publishing company

Scroll to Top